Insider Selling: Phreesia, Inc. (NYSE:PHR) General Counsel Sells 3,496 Shares of Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 3,496 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $25.32, for a total value of $88,518.72. Following the completion of the transaction, the general counsel now owns 139,134 shares in the company, valued at approximately $3,522,872.88. This trade represents a 2.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Phreesia Stock Performance

Phreesia stock opened at $29.08 on Thursday. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $30.53. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.71 billion, a P/E ratio of -19.78 and a beta of 1.03. The stock has a 50 day moving average of $27.33 and a 200-day moving average of $24.04.

Analysts Set New Price Targets

A number of analysts recently issued reports on PHR shares. Canaccord Genuity Group increased their target price on shares of Phreesia from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. KeyCorp raised their target price on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Wednesday, January 8th. Piper Sandler reaffirmed an “overweight” rating and set a $33.00 price target (up from $31.00) on shares of Phreesia in a research report on Wednesday, January 29th. JMP Securities restated a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a research note on Tuesday, December 10th. Finally, Robert W. Baird dropped their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $31.33.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in PHR. Vanguard Group Inc. increased its position in shares of Phreesia by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 4,823,110 shares of the company’s stock worth $121,349,000 after purchasing an additional 61,048 shares during the last quarter. Greenhouse Funds LLLP grew its stake in Phreesia by 27.9% in the fourth quarter. Greenhouse Funds LLLP now owns 2,873,892 shares of the company’s stock worth $72,307,000 after purchasing an additional 626,579 shares in the last quarter. Champlain Investment Partners LLC increased its holdings in Phreesia by 4.1% in the third quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock valued at $57,062,000 after buying an additional 97,847 shares during the last quarter. Franklin Resources Inc. raised its stake in Phreesia by 0.8% during the fourth quarter. Franklin Resources Inc. now owns 1,509,617 shares of the company’s stock valued at $37,982,000 after buying an additional 11,986 shares in the last quarter. Finally, State Street Corp lifted its holdings in Phreesia by 7.1% during the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after buying an additional 88,517 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.